MARKET

SCYX

SCYX

Scynexis
NASDAQ
1.445
-0.155
-9.69%
After Hours: 1.480 +0.035 +2.42% 19:35 04/12 EDT
OPEN
1.610
PREV CLOSE
1.600
HIGH
1.630
LOW
1.440
VOLUME
496.79K
TURNOVER
0
52 WEEK HIGH
3.870
52 WEEK LOW
1.350
MARKET CAP
54.55M
P/E (TTM)
1.043
1D
5D
1M
3M
1Y
5Y
Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects
TipRanks · 2d ago
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain in 2024. SCYNEXIS is a biotechnology company pioneering innovative medicines to overcome difficult-to-treat infections.
Barchart · 4d ago
Weekly Report: what happened at SCYX last week (0401-0405)?
Weekly Report · 5d ago
Scynexis: Update Following Restructuring Of GSK Deal
Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years, not accounting for pending milestone payments. The company is undervalued in the short/medium term, but its long-term success is unclear.
Seeking Alpha · 04/02 14:04
Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership
Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on SCYNEXIS (SCYX – Research Report) today and set a price target of $7.50. The biotechnology company is developing a drug for the treatment of serious fungal infections.
TipRanks · 04/02 10:46
SCYNEXIS INC <SCYX.O>: GUGGENHEIM CUTS TARGET PRICE TO $6 FROM $7
Reuters · 04/02 10:35
Cantor Fitzgerald Reiterates Overweight on SCYNEXIS
Benzinga · 04/01 12:31
Weekly Report: what happened at SCYX last week (0325-0329)?
Weekly Report · 04/01 09:41
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.